Aim Immunotech Inc Stock Ownership - Who owns Aim Immunotech?

Insider buying vs selling

Have Aim Immunotech Inc insiders been buying or selling?
Stewart AppelrouthDirector2023-03-1068,208$1.23
Stewart AppelrouthDirector2023-01-0380,646$0.31
Thomas K. EquelsCEO President2023-01-03161,291$0.31
Peter W. Rodino IiiCOO Secretary Gen. Counsel2023-01-0380,646$0.31
Thomas K. EquelsCEO & President2022-07-1832,895$0.76

1 of 1

AIM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AIM insiders and whales buy or sell their stock.

AIM Shareholders

What type of owners hold Aim Immunotech Inc stock?
William A. Carter4.37%2,116,170$1.01MInsider
Vanguard Group Inc4.11%1,988,704$950.60kInstitution
Blackrock Inc1.69%817,127$390.59kInstitution
Iraj Eqhbal Kiani1.30%630,886$301.56kInsider
Morgan Stanley1.26%610,577$291.86kInstitution
Thomas K. Equels1.15%556,995$266.24kInsider
Geode Capital Management LLC0.79%380,905$182.07kInstitution
Steven D. Spence0.43%209,410$100.10kInsider
Russel J. Lander0.43%207,983$99.42kInsider
Charles Thomas Bernhardt Iii0.37%177,420$84.81kInsider

1 of 3

AIM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AIM9.84%9.53%Net BuyingNet Selling
ONTX6.80%83.87%Net Selling
COCP0.75%99.25%Net BuyingNet Buying
ENTX9.83%3.81%Net BuyingNet Buying

Aim Immunotech Stock Ownership FAQ

Who owns Aim Immunotech?

Aim Immunotech (NYSEMKT: AIM) is owned by 9.84% institutional shareholders, 9.53% Aim Immunotech insiders, and 80.64% retail investors. William A. Carter is the largest individual Aim Immunotech shareholder, owning 2.12M shares representing 4.37% of the company. William A. Carter's Aim Immunotech shares are currently valued at $1.01M.

If you're new to stock investing, here's how to buy Aim Immunotech stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.